Literature DB >> 16488377

MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study.

Tijmen Korteweg1, Mar Tintoré, Bernard Uitdehaag, Alex Rovira, Jette Frederiksen, David Miller, Kryshani Fernando, Massimo Filippi, Federica Agosta, Maria Rocca, Franz Fazekas, Christian Enzinger, Paul Matthews, Allyson Parry, Chris Polman, Xavier Montalban, Frederik Barkhof.   

Abstract

BACKGROUND: The McDonald International Panel accepted the Barkhof/Tintoré criteria for providing MRI evidence of dissemination in space to allow a diagnosis of multiple sclerosis in patients with clinically isolated syndromes (CIS). We applied these criteria in a large cohort of patients with CIS, representative of those seen in a general diagnostic setting, to assess their accuracy in predicting conversion to definite multiple sclerosis and to identify factors that affect this risk.
METHODS: In a collaborative study of seven centres, baseline MRI and clinical follow-up data for 532 patients with CIS were studied, with the development of a second clinical event used as the main outcome. All scans were scored for lesion counts and spatial lesion distribution to assess the fulfilment--ie, at least three out of four--of the Barkhof/Tintoré criteria. We used survival analysis and 2x2 tables to assess the test characteristics of the criteria at baseline.
FINDINGS: Overall conversion rate was 32.5% with a median survival time of 85.3 months. Fulfilment of the criteria at baseline showed, after a survival time of 2 years, a conversion rate of about 45% (95% CI 37-53) versus about 10% (6-16) in those with no asymptomatic lesions at baseline (p<0.0001). For patients with a follow-up of at least 2 years, the fulfilment of the MRI criteria showed an accuracy of 68% (sensitivity 49%, specificity 79%) for predicting conversion and an increase in risk of nearly four times for conversion compared with those not fulfilling the criteria (odds ratio 3.7, 95% CI 2.3-5.9; p<0.0001). Cox proportional hazards regression analysis accorded with this increased risk. No effects were recorded on the performance of the criteria by sex, presenting symptoms, or centre. Age at baseline did have a small but significant effect as predictor (hazard ratio 0.97, 0.95-0.99; p=0.002), but did not affect the prognostic value of the MRI criteria.
INTERPRETATION: MRI abnormalities have important prognostic value. The cut-off, based on the Barkhof/Tintoré criteria, as incorporated in the McDonald diagnostic scheme yields acceptable specificity, but could have lower sensitivity than previously reported.

Entities:  

Mesh:

Year:  2006        PMID: 16488377     DOI: 10.1016/S1474-4422(06)70353-2

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  23 in total

1.  Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event.

Authors:  Jean-Christophe Corvol; Daniel Pelletier; Roland G Henry; Stacy J Caillier; Joanne Wang; Derek Pappas; Simona Casazza; Darin T Okuda; Stephen L Hauser; Jorge R Oksenberg; Sergio E Baranzini
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-08       Impact factor: 11.205

2.  Criteria improving multiple sclerosis diagnosis at the first MRI.

Authors:  Nathalie Caucheteux; Adil Maarouf; Margaux Genevray; Emmanuelle Leray; Romain Deschamps; Marie P Chaunu; Laure Daelman; Jean C Ferré; Olivier Gout; Jean Pelletier; Laurent Pierot; Gilles Edan; Ayman Tourbah
Journal:  J Neurol       Date:  2015-02-17       Impact factor: 4.849

Review 3.  [Radiologically isolated syndrome: multiple sclerosis based solely on MRI findings?].

Authors:  J Sellner; L Schirmer; B Hemmer; M Mühlau
Journal:  Nervenarzt       Date:  2010-10       Impact factor: 1.214

4.  The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS).

Authors:  Johannes Brettschneider; Anne Czerwoniak; Makbule Senel; Lubin Fang; Jan Kassubek; Elmar Pinkhardt; Florian Lauda; Tamara Kapfer; Sarah Jesse; Vera Lehmensiek; Albert C Ludolph; Markus Otto; Hayrettin Tumani
Journal:  PLoS One       Date:  2010-08-05       Impact factor: 3.240

5.  A three-year, multi-parametric MRI study in patients at presentation with CIS.

Authors:  Maria A Rocca; Federica Agosta; Maria P Sormani; Kryshani Fernando; Mar Tintorè; Tijmen Korteweg; Paola Tortorella; David H Miller; Alan Thompson; Alex Rovira; Xavier Montalban; Chris Polman; Frederik Barkhof; Massimo Filippi
Journal:  J Neurol       Date:  2008-02-18       Impact factor: 4.849

6.  Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study.

Authors:  Roberto D'Alessandro; Luca Vignatelli; Alessandra Lugaresi; Elisa Baldin; Franco Granella; Maria Rosaria Tola; Susanna Malagù; Luisa Motti; Walter Neri; Massimo Galeotti; Mario Santangelo; Laila Fiorani; Enrico Montanari; Cinzia Scandellari; Maria Donata Benedetti; Maurizio Leone
Journal:  J Neurol       Date:  2013-02-03       Impact factor: 4.849

7.  Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b.

Authors:  Chris Polman; Ludwig Kappos; Mark S Freedman; Gilles Edan; Hans-Peter Hartung; David H Miller; Xavier Montalbán; Frederick Barkhof; Krzysztof Selmaj; Bernard M J Uitdehaag; Susanne Dahms; Lars Bauer; Christoph Pohl; Rupert Sandbrink
Journal:  J Neurol       Date:  2007-11-15       Impact factor: 4.849

8.  Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis.

Authors:  Elizabeth M Cameron; Sade Spencer; Jonathan Lazarini; Christopher T Harp; E Sally Ward; Mark Burgoon; Gregory P Owens; Michael K Racke; Jeffrey L Bennett; Elliot M Frohman; Nancy L Monson
Journal:  J Neuroimmunol       Date:  2009-07-24       Impact factor: 3.478

9.  MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome.

Authors:  Jessica M Nielsen; Christoph Pohl; Chris H Polman; Frederik Barkhof; Mark S Freedman; Gilles Edan; David H Miller; Lars Bauer; Rupert Sandbrink; Ludwig Kappos; Bernard M J Uitdehaag
Journal:  BMC Neurol       Date:  2009-05-20       Impact factor: 2.474

10.  IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome.

Authors:  Johannes Brettschneider; Hayrettin Tumani; Ulrike Kiechle; Rainer Muche; Gayle Richards; Vera Lehmensiek; Albert C Ludolph; Markus Otto
Journal:  PLoS One       Date:  2009-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.